InpharmD™ Blogs


Transforming Type 2 Diabetes Treatment: Key Findings from the QWINT-2 (once-weekly insu...

Transforming Type 2 Diabetes Treatment: Key Findings from the QWINT-2 (once-weekly insulin therapy) Trial Written by Tanmaya Phanda, PharmD,  InpharmD Team This blog will provide an overview of type 2 diabetes, explore key insights from the QWINT-2 trial, and dis...

Posted


New FDA Approval: COBENFY™ (xanomeline and trospium)

The U.S. Food and Drug Administration recently approved Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a first-in-class muscarinic agonist for the treatment of schizophrenia in adults. Read InpharmD's summary below: Drug Name COBENFY™ (x...

Posted


New FDA Approval: AQNEURSA™ (levacetylleucine)

the U.S. Food and Drug Administration (FDA) has approved AQNEURSA™ (levacetylleucine) for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg. AQNEURSA is the only FDA-approved stand-alone...

Posted


New FDA Approval: MIPLYFFA™ (arimoclomol)

The US Food and Drug Administration (FDA) recently approved Miplyffa (arimoclomol), a medication for Niemann-Pick disease type C (NPC) to improve neurological symptoms and stop disease progression. Read InpharmD's summary below: Drug Name MIPLYFFA™ (arimoclo...

Posted


New FDA Approval: OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq)

The U.S. Food and Drug Administration (FDA) recently approved Ocrevus Zunovo™ (ocrelizumab & hyaluronidase-ocsq, Genentech) as a twice-a-year healthcare professional (HCP)-administered approximately 10-minute subcutaneous (SC, under the skin) injectable disea...

Posted


New FDA Approval: EBGLYSS™ (lebrikizumab-lbkz)

The US Food and Drug Administration (FDA) recently approved EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis.  Read InpharmD's summary below: Drug Name EBGLYSS™ (lebrikizumab-lbkz) Active ...

Posted


New FDA Approval: TECENTRIQ HYBREZA™ (atezolizumab and hyaluronidase-tqjs)

The Food and Drug Administration (FDA) approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) for subcutaneous injection for all the adult indications as the intravenous formulation of atezolizumab (Tecentriq, Genentech, Inc.), including no...

Posted


New FDA Approval: PAVBLU™ (aflibercept-ayyh)

PAVBLUTM (aflibercept-ayyh) is an FDA-approved biosimilar to EYLEA® (aflibercept) indicated for the treatment of patients with:* Neovascular (Wet) Age‑Related Macular Degeneration (AMD) Macular Edema Following Retinal Vein Occlusion (RVO) Diabetic Macular Edema (D...

Posted


Alternative Agents for Dihydroergotamine Mesylate in Management of Cluster Headaches an...

Headaches are multifactorial and a common occurrence among the general population, with a subset of patients experiencing more severe forms, such as cluster headaches or migraines. Patients with these conditions often require pharmacological interventions for prophyl...

Posted


Evaluating Dexmedetomidine: A Viable Non-Opioid Alternative to Remifentanil in Anesthes...

Introduction Fentanyl and its analogs, such as remifentanil, sufentanil, and alfentanil, are vital components of modern anesthesia and pain management, valued for their rapid onset, potent analgesic effects, and ability to maintain hemodynamic stability during surgi...

Posted


Maintaining Weight Loss: The Efficacy of Long-Term Tirzepatide Therapy

Obesity is the most prevalent chronic condition worldwide, affecting more than 13% of the adult population. Excessive adiposity, along with its associated complications such as cardiovascular disease and type 2 diabetes, imposes a substantial economic burden and is a...

Posted


New FDA Approval: NIKTIMVO™ (axatilimab-csfr)

The U.S Food and Drug Administration recently approved approved axatilimab-csfr (Niktimvo, Incyte Corporation), a colony stimulating factor-1 receptor-blocking antibody, for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prio...

Posted


New FDA Approval: LIVDELZI® (seladelpar)

The U.S Food and Drug Administration (FDA) recently approved Livdelzi® (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients...

Posted


New FDA Approval: NEMLUVIO® (nemolizumab-ilto)

The U.S Food and Drug Administration recently approved Nemluvio® (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. Nemluvio was granted Breakthrough Therapy Designation in December 2019 and Priority Revie...

Posted


New FDA Approval: YORVIPATH®(palopegteriparatide)

The U.S Food and Drug Administration (FDA) recently approved YORVIPATH® (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults. YORVIPATH is a prodrug of parathyroid hormone (PTH[1-34]), administered once daily, designed to...

Posted


New FDA Approval: ENZEEVU™(aflibercept-abzv)

The U.S Food and Drug Administration (FDA) recently approved approved Enzeevu™ (aflibercept-abzv), a 2 mg vial kit and pre-filled syringe for intravitreal injection. Enzeevu™ is indicated to improve and maintain visual acuity in patients with neovascular age-related ...

Posted


New FDA Approval: NEFFY® (epinephrine)

The U.S Food and Drug Administration (FDA) recently approved approved Neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis), in adult and pediatric patients who weigh at lea...

Posted


New FDA Approval: LYMPHIR™(denileukin diftitox-cxdl)

The U.S Food and Drug Administration recently approved Lymphir (denileukin diftitox-cxdl),  an IL2-receptor-directed cytotoxin indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior sys...

Posted


New FDA Approval: CREXONT® (carbidopa and levodopa)

The U.S Food and Drug Administration recently approved Crexont for the treatment of Parkinson’s disease. It contains a new formulation of immediate-and extended-release levodopa with carbidopa. Read InpharmD's summary below: Drug Name CREXONT® (carbidopa and...

Posted


New FDA Approval: ZURNAI™ (nalmefene)

The U.S Food and Drug Adminstration (FDA) recently approved ZURNAI™, the first nalmefene hydrochloride auto-injector for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older. Drug Name ZURNAI...

Posted


New FDA Approval: VORANIGO® (vorasidenib)

The U.S Food and Drug Administration (FDA) recently approved VORANIGO® (vorasidenib), a prescription medicine used to treat adults and children 12 years of age and older with certain types of brain tumors called astrocytoma or oligodendroglioma with an isocitrate deh...

Posted


New FDA Approval: TECELRA® (afamitresgene autoleucel)

The U.S Food and Drug Administration (FDA) recently approved Tecelra (afamitresgene autoleucel), a gene therapy indicated for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA antigen(s) A*02:01P, -...

Posted


New FDA Approval: LAZCLUZE™ (lazertinib)

The U.S Food and Drug Administration recently approved RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor recepto...

Posted


Addressing Topical Steroid Withdrawal: Insights into Diagnosis and Treatment

Addressing Topical Steroid Withdrawal: Insights into Diagnosis and Treatment Since 2015, patient-led conversations about topical steroid withdrawal (TSW) have quickly grown on social media. Patients are often troubled by the potential adverse effects of topical cort...

Posted


Medication Management in Obesity: A Look at Pediatrics and Adult Treatments

Medication Management in Obesity: A Look at Pediatrics and Adult Treatments Obesity is an ever-increasing global health concern and a major modifiable risk factor for the development of comorbid conditions such as cardiovascular disease, osteoarthritis, and some for...

Posted


Comparing Semaglutide and Tirzepatide for Weight Loss in Overweight and Obese Adults: R...

Comparing Semaglutide and Tirzepatide for Weight Loss in Overweight and Obese Adults: Real-World Data Insights Obesity is a chronic disease with high prevalence and numerous comorbidities, such as type 2 diabetes (T2D), hypertension, ventilatory dysfunction, arthros...

Posted


New FDA Approval: FEMLYV™ (ethinyl estradiol and norethindrone acetate)

The U.S. Food and Drug Administration (FDA) approved Femlyv (norethindrone acetate and ethinyl estradiol), the first orally disintegrating tablet approved for the prevention of pregnancy. Norethindrone acetate and ethinyl estradiol, the main ingredients in Femlyv, ha...

Posted


New FDA Approval: EPYSQLI™(eculizumab-aagh)

The U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Epysqli (eculizumab-aagh) as a biosimilar to Soliris (eculizumab). Epysqli has been approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (P...

Posted


New FDA Approval: KISUNLA™ (donanemab-azbt)

The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD), which includes p...

Posted


New FDA Approval: PYZCHIVA® (ustekinumab-ttwe)

The FDA has approved Samsung Bioepis’ Pyzchiva (ustekinumab-ttwe) for the treatment of inflammatory conditions, including plaque psoriasis and ulcerative colitis. Pyzchiva marks the third biosimilar referencing Stelara (ustekinumab) to be approved for the American ma...

Posted


New FDA Approval: AHZANTIVE® (aflibercept-mrbb)

The US Food and Drug Administration (FDA) has approved biosimilar to Eylea, aflibercept-mrbb (Ahzantive), for the treatment of patients with age-related neovascular (wet) macular degeneration (nAMD). The biosimilar has also been approved for treatment in patients wi...

Posted


New FDA Approval: OHTUVAYRE™ (ensifentrine)

The U.S. Food and Drug Administration (FDA) recently approved OHTUVAYRE™  (ensifentrine). OHTUVAYRE™ is the first inhaled product with a novel mechanism of action available for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patient...

Posted


New FDA Approval: PIASKY™ (crovalimab-akkz)

The US Food and Drug Administration (FDA) recently approved PIASKY™ (crovalimab-akkz) for the treatment of adult and pediatric patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) and body weight of at least 40 kg. Read InpharmD's clinical summa...

Posted


Understanding Interchangeable Biosimilars

Understanding Interchangeable Biosimilars A biosimilar is a biologic drug highly similar to a reference product, with no clinically meaningful differences in safety, purity, and potency. An interchangeable biosimilar can be substituted at the pharmacy for the refere...

Posted


New FDA Approval: SOFDRA™ (sofpironium)

The US Food and Drug Administration (FDA) has approved Botanix Pharmaceutical's sofpironium (Sofdra) topical gel, 12.45% for adults and children ages 9 and older with primarily axillary hyperhidrosis. It is now the first and only chemical entity approved for this ind...

Posted


New FDA Approval: YIMMUGO® (immune globulin intravenous, human-dira) Liquid for Intrave...

The U.S Food and Drug Administration (FDA) recently approved YIMMUGO® (immune globulin intravenous, human-dira), an innovative intravenous immunoglobulin (Ig) therapeutic, to treat primary immunodeficiencies (PID). Read InpharmD's summary below:  Drug Name Y...

Posted


New FDA Approval: VIGAFYDE™ (vigabatrin) Oral Solution

The U.S. Food and Drug Administration (FDA) recentlhy approved VIGAFYDE™, the only ready-to-use vigabatrin oral solution. VIGAFYDE™ (vigabatrin) oral solution, is indicated as a monotherapy for the treatment of pediatric patients 1 month to 2 years of age with infant...

Posted


New FDA Approval: CAPVAXIVE™ (pneumococcal 21-valent conjugate vaccine) Injection

The U.S Food and Drug Administration (FDA) recently approved CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults. Read InpharmD's summary below: Drug Name CAPVAXIVE™ ...

Posted


New FDA Approval: Iqirvo® (elafibranor)

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Iqirvo® (elafibranor) 80 mg tablets for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UD...

Posted


New FDA Approval: RYTELO™ (imetelstat)

On June 6, 2024, the Food and Drug Administration approved imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring four or...

Posted


New FDA Approval: MRESVIA™ (Respiratory Syncytial Virus Vaccine, mRNA)

The U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a b...

Posted


New FDA Approval: BKEMV™ (eculizumab-aeeb)

The Food and Drug Administration recently approved BKEMV™. This is the first biosimilar to reference Soliris (eculizumab), for the treatment of two rare diseases: paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).  Of note, BKEM...

Posted


Assessing Humira® (adalimumab) Biosimilars

The Buzz Around Biosimilars A biosimilar drug, as defined by the US Food and Drug Administration (FDA), is a biopharmaceutical that is highly similar to an already licensed biologic product, known as the reference product. Despite minor differences in clinically ina...

Posted


New FDA Approvals: YESAFILI™(aflibercept-jbvf) and OPUVIZ™(aflibercept-yszy)

The Food and Drug Administration (FDA) recently approved YESAFILI™(aflibercept-jbvf) and OPUVIZ™(aflibercept-yszy) as interchangeable biosimilars to Eylea (aflibercept).  Both drugs are used to treat neovascular (wet) age-related macular degeneration, macular edema ...

Posted


New FDA Approval: IMDELLTRA™ (tarlatamab-dlle)

The Food and Drug Administration (FDA) recently approved IMDELLTRA™ (tarlatamab-dlle), a bispecific T-cell engager (BiTE) for the treatment of small cell lung cancer (SCLC) that has progressed on or after platinum-based chemotherapy. It marks the first BiTE therapy a...

Posted


New FDA Approval: MYHIBBIN™ (mycophenolate mofetil)

The Food and Drug Administration (FDA) has approved mycophenolate mofetil oral suspension (MYHIBBIN™), an antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in both adults and pediatric recipients (aged 3 months and older) of allogenic kidn...

Posted


New FDA Approval: XOLREMDI™

The Food and Drug Administration (FDA) recently approved XOLREMDI™ – a CXC chemokine receptor 4 (CXCR4) antagonist indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number o...

Posted


New FDA Approval: ANKTIVA® (nogapendekin alfa inbakicept-pmln)

The Food and Drug Administration (FDA) approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC) with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) wit...

Posted


New FDA Approval: LUMISIGHT™ (pegulicianine)

The Food and Drug Administration (FDA) recently approved Lumisight (pegulicianine) in adults with breast cancer to assist the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery....

Posted


Dexmedetomidine – Preventing Postpartum Depression

Exploring Dexmedetomidine's Potential Role in Preventing Postpartum Depression Postpartum depression (PPD) affects approximately 10% to 20% of women following childbirth, making it the most prevalent psychological disorder in this demographic, and thus, a clinically...

Posted


Alternative Dosing for Meropenem

Evidence Behind Alternative Dosing of Meropenem Inappropriate antibiotic use is a significant concern for healthcare systems worldwide, as it can lead to adverse patient outcomes, promote antibiotic resistance, and impose economic burdens. This issue underscores the...

Posted


New FDA Approval: SELARSDI™(ustekinumab-aekn)

The Food and Drug Administration (FDA) recently approved SELARSDI™(ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patie...

Posted


New FDA Approval: RISVAN® (risperidone)

The Food and Drug Administration (FDA) has approved Risvan® (risperidone for extended-release injectable suspension) for the treatment of adults with schizophrenia. Read InpharmD's summary below: Drug Name RISVAN® Active Ingredient risperidone Dat...

Posted


New FDA Approval: ZEVTERA® (ceftobiprole medocaril sodium)

The U.S. Food and Drug Administration approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis; adults with...

Posted


New FDA Approval: VOYDEYA™ (danicopan)

The Food and Drug Administration (FDA) recently approved VOYDEYA™, the first-in-class, oral, Factor D inhibitor based on results from pivotal ALPHA Phase III trial.   Drug Name VOYDEYA™ Active Ingredient danicopan Date of Approval 3/29/24 Ma...

Posted


New FDA Approval: TRYVIO™ Summary

New FDA Approval: TRYVIO™ (aprocitentan) Summary The Food and Drug Administration (FDA) recently approved TRYVIO™ (aprocitentan) for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not...

Posted


New FDA Approval: LENMELDY™ (atidarsagene autotemcel) Summary

The Food and Drug Administration (FDA) approved LENMELDY™ (atidarsagene autotemcel), the first FDA-approved gene therapy indicated for the treatment of children with pre-symptomatic late infantile, pre-symptomatic early juvenile or early symptomatic early juvenile me...

Posted


New FDA Approval: REZDIFFRA™ (resmetirom) Summary

The Food and Drug Administration Recently Approved REZDIFFRA™ (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise.  Read the Inph...

Posted


New FDA Approval: Wyost (denosumab-bbdz) Summary

The Food and Drug Administration (FDA) recently approved Wyost (denosumab-bbdz) injection as an interchangeable biosimilar to U.S.-licensed Xgeva (denosumab).  Read the InpharmD summary below: Drug Name Wyost (denosumab-bbdz) Injection Active Ingredient...

Posted


New FDA Approval: Jubbonti (denosumab) Summary

The Food and Drug Administration (FDA) recently approved Jubbonti (denosumab-bbdz) injection as an interchangeable biosimilar to U.S.-licensed Prolia (denosumab).  Read the InpharmD summary below: Drug Name Jubbonti (denosumab-bbdz) Injection Active Ing...

Posted


New FDA Approval: Tyenne® (tocilizumab-aazg) Summary

The Food and Drug Administration (FDA) has approved Tyenne® (tocilizumab-aazg), the first biosimilar to Actemra® (tocilizumab) for both intravenous (IV) and subcutaneous (SC) administration.  Check out InpharmD's summary below: Drug Name Tyenne® (tocilizumab...

Posted


The American Diabetes Association® (ADA) Standards of Care 2024 Update

The American Diabetes Association® (ADA) Standards of Care 2024 Update Diabetes mellitus is a metabolic disorder characterized by elevated blood glucose levels. The primary subtypes are type 1 diabetes mellitus and type 2 diabetes mellitus, distinguished by defects ...

Posted


New FDA Approval: TEVIMBRA™ Summary

The Food and Drug Administration (FDA) has approved tislelizumab-jsgr (TEVIMBRA™) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) following prior systemic chemotherapy that did not include a PD-1/PD-L1 ...

Posted


TRUQAP™ (capivasertib) Approval for Breast Cancer Treatment

TRUQAP™ (capivasertib) Approval for Breast Cancer Treatment Breast cancer, which is the most diagnosed cancer and the primary cause of cancer-related deaths in women globally, is predominantly characterized by hormone receptor positive, human epidermal growth factor...

Posted


Doxycycline Post Exposure Prophylaxis for Sexually Transmitted Infections

Doxycycline Post Exposure Prophylaxis for Sexually Transmitted Infections Where We Are and Where We Are Going Over 26 million sexually transmitted infections (STIs) are reported each year in the United States alone. In 2018, one in every five Americans reported hav...

Posted


A Retrospective Analysis of InpharmD's Drug Information Inquiries

A Retrospective Analysis of InpharmD's Drug Information Inquiries Background: Drug information is a specialty area within the realm of clinical pharmacy that has evolved as technology and clinical practice have changed over time. Due to the nature and complexity of c...

Posted


InpharmD Process: How we answer questions
InpharmD 2023 Top Questions

We know you enjoy data as much as we do, and thought you'd be interested in seeing ours. We answered thousands of questions and now have 50 million+ studies in our bank! Here were the most popular topics in 2023: 1. What is the risk of serot...

Posted


Announcing Our $6.05m Seed Round

InpharmD, An AI-Based Drug Information Service, Announces $6.05M in Funding   Atlanta, GA - December, 11 2023 - InpharmD, an AI-based drug information service, announced the close of a $6.05M oversubscribed seed round, led by 645 Ventures, a healthcare and ...

Posted


Exclusive: InpharmD seeds $6M for on-demand drug info

Why it matters: Hospitals face pressing challenges accessing reliable drug information amid staffing problems and rising drug costs. Details:The round was led by 645 Ventures. Other participants include Atlanta Ventures, Y Combinator, QlarantCapital and SF ELC. ...

Posted


Decoding InpharmD - Revolutionizing Drug Information with AI

Hospitals are grappling with the demanding task of accessing reliable drug information. Impediments such as paywalls and the limited time clinicians have to manually sift through literature pose significant challenges. On top of this, the healthcare industry is feeli...

Posted